Gibbs Wealth Management Acquires 13,968 Shares of Bristol Myers Squibb Company $BMY

Posted by Brenda Bartman on Jul 24th, 2026

Gibbs Wealth Management boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 107.9% in the 1st quarter, HoldingsChannel.com reports. The firm owned 26,915 shares of the biopharmaceutical company’s stock after purchasing an additional 13,968 shares during the period. Gibbs Wealth Management’s holdings in Bristol Myers Squibb were worth $1,632,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in BMY. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $25,000. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Physician Wealth Advisors Inc. increased its stake in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: BMY was highlighted as rising while the broader market dipped, suggesting investors were rotating into the name and viewing it as relatively resilient versus the market. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Positive Sentiment: Wall Street expectations point to earnings growth in next week’s report, and multiple articles framed Bristol Myers Squibb as having a strong chance to beat estimates, which can support the stock into the print. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Positive Sentiment: An analyst-style momentum piece also described BMY as a top long-term momentum stock, reinforcing a constructive technical/relative-strength narrative. Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
Neutral Sentiment: Bristol Myers Squibb is scheduled to report quarterly earnings next week, keeping the stock in a wait-and-see mode as investors look for confirmation of growth and guidance. Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday
Neutral Sentiment: News that Alexandria Real Estate delivered a new Bristol Myers Squibb R&D hub in San Diego is operationally positive, but it is more of a long-term business development update than an immediate stock catalyst. Alexandria Real Estate Equities Delivers 427,000 RSF Bristol Myers Squibb R & D Hub
Negative Sentiment: One MarketWatch item noted BMY underperformed peers despite daily gains, which suggests the move may be less impressive on a relative basis than it first appears. Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains

Analyst Upgrades and Downgrades

A number of research firms recently commented on BMY. Bank of America lowered their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Weiss Ratings cut Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 16th. Eight research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $61.25.

View Our Latest Stock Analysis on BMY

Bristol Myers Squibb Trading Up 1.3%

NYSE BMY opened at $61.56 on Friday. The firm has a market capitalization of $125.71 billion, a PE ratio of 17.29, a P/E/G ratio of 0.17 and a beta of 0.23. The stock’s 50 day moving average is $57.39 and its 200 day moving average is $58.00. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the firm posted $1.80 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Bristol Myers Squibb Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.